HAHabibe Sema Arslan

Habibe Sema Arslan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Habibe Sema Arslan has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IN SILICO TOXICITY PROFILING OF BENZOPHENONE-3 WITH FOCUS ON DEVELOPMENTAL AND METABOLIC PATHWAYS

    by Mehmethan Yıldırım, Neslihan Özdemir, Serap Yalcin Azarkan, Habibe Sema Arslan Unal

    Objective: This study aims to evaluate the developmental toxicity potential of Benzophenone-3 (BP-3), a widely used ultraviolet (UV) filter in personal care products, through in silico analyses.Material and Method: The toxicological properties of BP-3 were predicted using the ProTox and deTOX platforms. Developmental toxicity was modeled specifically for the first, second, and third trimesters of pregnancy. Additionally, the potential interactions of BP-3 with human cytochrome P450 enzymes (CYP1A2, CYP2C19, CYP2D6) were investigated via molecular docking analyses.Result and Discussion: Literature data confirm that BP-3 can cross the placental barrier and enter systemic circulation. In silico predictions indicated a high developmental toxicity potential, particularly during the second trimester (probability: 0.952). Molecular docking analyses revealed strong binding affinity of BP-3 to CYP1A2, as well as notable interactions with CYP2C19 and CYP2D6, suggesting possible interference with drug metabolism and endocrine regulation. The findings were further supported by structural toxicity contribution mapping, highlighting specific molecular regions responsible for toxicity.

  • Open Access

    Cytotoxic and Metastatic Effects of Bee Products in the MDA-MB-231 Breast Cancer Model: A Comparative Study

    by Habibe Sema Arslan, Serap Yalcin

    Purpose: This study aimed to comparatively evaluate the cytotoxic and anti-metastatic effects of four bee products—propolis, royal jelly, bee bread, and bee venom—obtained from the Kırşehir region on the MDA-MB-231 triple-negative breast cancer cell line.Materials and Methods: Cell viability was assessed using the XTT assay, while migration and invasion were evaluated by wound healing and invasion assays. IC₅₀ values were determined for each bee product, and treatments were applied at these concentrations under controlled experimental conditions. Image analysis was performed using ImageJ software, and statistical analyses were conducted using SPSS 29 and GraphPad Prism 8 software packages.Results: All bee products suppressed cell proliferation in a dose-dependent manner. Propolis (IC₅₀: 40 µg/mL) and bee venom (IC₅₀: 4.5 µg/mL) showed the strongest cytotoxicity, whereas bee bread and royal jelly exhibited IC₅₀ values of 195 µg/mL and 426 µg/mL, respectively. Wound healing assays demonstrated that cell migration was significantly reduced in propolis, bee venom, and bee bread groups after 48 hours (p<0.001 for all groups), while no significant change was observed with royal jelly (p=0.121). In invasion assays, propolis significantly reduced matrix penetration (p=0.001), and bee venom (p<0.001) and bee bread (p=0.041) also demonstrated significant anti-invasive effects.Conclusion: Propolis and bee venom were the most effective agents in inhibiting cell migration and invasion. Bee products exhibit notable anticancer potential in MDA-MB-231 cells and may serve as promising complementary therapeutic agents. Further comprehensive studies are required to confirm these findings and elucidate the underlying molecular mechanisms in detail.

  • Investigation of cytotoxic, molecular and in silico effects of chlorambucil and tamoxifen on 2D/3D MDA-MB-231 and HeLa cancer cell models

    by Durmuş Burak Demirkaya, Habibe Sema Arslan, Serap Yalcin Azarkan

    This study aimed to investigate the cytotoxic, morphological, and molecular effects of Tamoxifen (TMX) and Chlorambucil (CHL) on breast cancer (MDA-MB-231) and cervical cancer (HeLa) cell lines. The impact of these agents on metastatic behavior, apoptotic mechanisms, and gene expression profiles was examined in both two-dimensional (2D) and three-dimensional (3D) cell culture models. Cells were treated with varying concentrations of TMX and CHL. Cytotoxicity was assessed using the XTT assay, and morphological changes were monitored by microscopy. Migration and invasion assays assessed metastatic potential. VEGFA expression was quantified by qRT-PCR. In 3D cultures, treatment responses were evaluated based on size reduction and structural changes in hydrogel-based spheroids. Docking analysis was conducted to determine binding affinities of TMX and CHL. TMX and CHL exhibited dose-dependent effects on breast and cervical cancer cells. Combination treatment led to significantly greater reductions in cell viability compared to controls (p < 0.05). Moreover, VEGFA expression was markedly reduced in both 2D and 3D models (p < 0.05). These findings support the potential therapeutic value of TMX and CHL. Docking analysis revealed highly negative binding energies, consistent with in vitro results, indicating synergistic interaction at molecular and cellular levels. TMX and CHL combination therapy demonstrated potent anti-cancer activity in breast and cervical cancer models, reducing cell viability, metastatic capacity, and VEGFA expression. These results suggest that TMX and CHL, when used together, may represent a promising strategy for developing synergistic and targeted cancer therapies. Further in vivo and clinical validation is warranted.

  • Open Access

    Cytotoxic and Metastatic Effects of Anatolian Propolis and Chemotherapeutic Agents (DOX, TAM, CLB) in 2D and 3D Breast Cancer Models

    by Habibe Sema Arslan, Serap Yalçın Azarkan, Gamze Turna Saltoğlu

    This study aims to comparatively investigate the cytotoxic and metastatic effects of Anatolian propolis and chemotherapeutic agents (Doxorubicin- DOX, Tamoxifen- TAM, Chlorambucil- CLB) on two-dimensional (2D) and three-dimensional (3D) breast cancer cell cultures. The triple-negative MDA-MB-231 breast cancer cell line was cultured in 2D and 3D models. Anatolian propolis was prepared using ethanol extraction and applied to the cells alone or in combination with chemotherapeutic agents (DOX, TAM, CLB) at their respective IC50 doses. Cytotoxicity was assessed using the XTT assay, while cell migration and invasion were evaluated using wound healing and invasion assays. Propolis, when combined with chemotherapeutic agents, significantly inhibited cell proliferation and migration (p


  • Open Access

    Determination of HLA Tissue Type According to the Etiology of Patients with Chronic Renal Failure

    by Burcu Karakus Turan, Fahri Ucar, Vural Taner Yilmaz, Yahya Kilinc, Sule Darbaş Aras, Huseyin Kocak, Nurten Sayin Ekinci, Bulent Aydinli, Habibe Sema Arslan

    Chronic kidney disease (CKD) is a prominent public health concern, is defined as functional and structural damage to the kidneys. This study aims to investigate the association between human leukocyte antigen (HLA) alleles individuals with CKD and the different etiological subgroups of diesease. Genomic DNA was obtained from peripheral blood samples of 1,079 patients with retrospective CKD and 1,111 healthy control individuals. HLA genotyping was conducted using the Luminex based low-resolution method. Allele frequency distributions were calculated with the help of Arlequin v3.11 population genetics statistics program and SPSS v23.0 program, and p<0.05 values were accepted as significant by chi-square tests. HLA A*02 (21.83%), B*35 (18.30%), DRB1*11 (21.41%) alleles were observed most frequently in individuals with CKD, respectively. In our study, B*08, B*49, B*50 alleles in the HLA B locus (p=0.002, p=0.012 p=0.009) and DRB1*03, *04 alleles in the HLA DRB1 locus (p<0.001, p<0.001) were found positively associated with CKD. A*02, A*11, A*74 alleles at the HLA A locus (p=0.003, p<0.001, p=0.009) and B*27, B*39, B* alleles at the HLA B locus 40, B*59 (p<0.001, p<0.001, p<0.001, p=0.009), DRB1*07, *08, *09, *13, *16 (p<0.001, p=0.012, p=0.007, p<0.001, p<0.001) alleles were determined as negatively associated with the disease. Among the etiological groups of CKD, cystic kidney disease (36.8%), hypertension (16.8%) and urological anomalies (16.6%) were negatively associated with the HLA-DR*13 allele. Since CKD shows serious morbidity and mortality, this comprehensive study of HLA subgroups gave an explanatory idea about which alleles associated with the disease in terms of susceptibility and protection.

  • Influence of ESR1 Variants on Clinical Characteristics and Fibromyalgia Syndrome in Turkish Women

    by Habibe Sema Arslan, Ayse Feyda Nursal, Ahmet Inanir, Nevin Karakus, Serbulent Yigit

    Background: Fibromyalgia syndrome (FMS) is characterized by widespread musculoskeletal pain. It is more common in women than in men, and sex hormones may play a role in this predominance. Therefore, this research investigated the clinical findings among Turkish females and whether Estrogen-α (ESR1) gene variants are associated with FMS. Methods: A total of 219 individuals were enrolled in this study. ESR1 variants (PvuII/XbaI) were genotyped using PCR-RFLP methods. The results of the analyses were evaluated for statistical significance. Results: There was a significant association between the ESR1 PvuII and FMS risk among Turkish women. The ESR1 PvuII CC genotype and C allele were higher in the patients than those in the controls (p=0.021, p=0.007, respectively). A more statistically significant association was observed between the patients and the controls in terms of TT genotype vs. TC+CC genotypes (p=0.022). Also, there was a statistically significant association between the patients and the controls in terms of TT+TC genotype vs. CC genotypes (p =0.028). There was no significant association between patients and the control group concerning the genotype distribution and allele frequencies of ESR1 XbaI (p>0.05). Headache was seen more frequently in the XbaI GA genotype (p=0.025), while XbaI AA genotype was associated with dysmenorrhea in patients with FMS (p=0.041). Conclusion: Our results indicate that ESR1 PvuII/XbaI variants are possibly effective in the development of FMS and some clinical features.